Read by QxMD icon Read

Intravesical bladder

Fayez Hammad, George Fidal
OBJECTIVE: To report on a case of intravesical explosion during transurethral resection of prostate (TURP) which was managed laparoscopically and to review the relevant literature. CLINICAL PRESENTATION AND INTERVENTION: During TURP, a loud explosion was heard and a jolt was felt in abdomen. A bladder tear was seen endoscopically. Systematic laparoscopic exploration showed no injury to abdominal organs apart from the irregular large bladder tear which was repaired laparoscopically...
October 11, 2018: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
Estela Noguera-Ortega, Rosa M Rabanal, Elisabet Gómez-Mora, Cecilia Cabrera, Marina Luquin, Esther Julián
The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical administration of live Mycobacterium bovis BCG. Previous studies suggest improving this therapy by implementing non-pathogenic mycobacteria, such as Mycobacterium brumae, and/or different vehicles for mycobacteria delivery, such as an olive oil (OO)-in-water emulsion. While it has been established that BCG treatment activates the immune system, the immune effects of altering the mycobacterium and/or the preparation remain unknown...
October 10, 2018: Scientific Reports
F J P van Valenberg, J A Witjes, B Aklan, S F de Jong, H Zegers, E Oosterwijk
INTRODUCTION: Several techniques can be used to treat intravesical chemohyperthermia (ChHT). We compared radiofrequency-induced hyperthermia (RF-HT) with conductive hyperthermia (C-HT) for their ability to induce bladder wall temperatures of >40.5 °C, the target temperature for ChHT. MATERIALS AND METHODS: Fresh porcine bladders (n = 12) were placed in a temperature-controlled saline bath to simulate body temperature and circulation. HT was induced with RF-HT (43 °C) or C-HT (inflow temperature 44 and 46 °C) using a custom-made device...
October 10, 2018: International Journal of Hyperthermia
Francis P Young, David Ende, Richard J Epstein
Progress in the management of non-muscle invasive bladder cancer has been slow. Despite longstanding use of intravesical therapies (e.g., Bacille Calmette-Guerin, BCG) to complement cystoscopic resection of high-grade lesions, many patients still develop recurrences requiring cystectomy, while others suffer side-effects of BCG without definite benefit. Many questions remain: for example, how many patients receive intravesical prophylaxis without efficacy? Which high-risk patients are best managed with early cystectomy? Could systemic therapies and/or radiotherapy extend bladder preservation times? Such questions may soon be refined by clinicopathologic non-muscle invasive bladder cancer signatures that predict sensitivity to cytotoxic, immune and targeted therapies...
October 10, 2018: Future Oncology
Jee Soo Park, Hae Do Jung, Young Sam Cho, Mei Hua Jin, Chang Hee Hong
PURPOSE: To evaluate whether mild chemical irritation of the bladder in neonatal rats is associated with persistent vanilloid receptor transient receptor potential vanilloid subfamily 1 (TRPV1) activity in adult rats. METHODS: Female Sprague-Dawley rats were used. Ten-day-old rat pups underwent bladder sensitization via intravesical infusion of 0.2% acetic acid in saline with or without prior bladder desensitization with capsaicin. After 8 weeks, 3 groups of rats (control [group 1], bladder sensitization [group 2], and bladder desensitization [group 3]) underwent cystometry...
September 2018: International Neurourology Journal
Pei-Lin Shen, Ming-En Lin, Ying-Kai Hong, Xue-Jun He
BACKGROUND: High-grade non-muscle-invasive bladder cancer is superficial; nonetheless, it is an aggressive cancer. Proper management strategy selection following transurethral resection between bladder preservation (BP) and radical cystectomy (RC) could result in delayed or excessive treatment. Hence, selecting the optimal treatment modality remains controversial to date. METHODS: We searched MEDLINE, The Cochrane Library, EMBASE, China National Knowledge Infrastructure, and Wanfang database through 12 April 2018...
October 2, 2018: World Journal of Surgical Oncology
Andrea Mogorovich, Cesare Selli, Alessio Tognarelli, Francesca Manassero, Maurizio De Maria
BACKGROUND: The introduction of foreign bodies in the female urethra for auto-erotic stimulation or in case of psychiatric disorders is not uncommon. The occurrence of intravesical migration of these objects makes it necessary to remove it shortly after insertion, since after long term permanence complications are likely to occurr. CASE PRESENTATION: A 47-year-old white female was referred at our Urology department for migration inside the bladder of a metallic urethral dilator used for sexual stimulation...
October 3, 2018: BMC Urology
Salvatore Siracusano, Tommaso Silvestri, Silvia Bassi, Antonio Benito Porcaro, Maria Angela Cerruto, Renato Talamini, Walter Artibani
INTRODUCTION: To evaluate health-related quality of life (HRQoL) in patients with non-muscle invasive bladder cancer (NMIBC) during the induction phase of intravesical instillations with BCG or MMC. MATERIALS AND METHODS: HRQoL was measured by two questionnaires from EORTC (QLQ-C30 and QLQ-BLS24), stratifying results by gender, age and therapy at the start of the therapy (T0), at last instillation (T1) and at 3 months after T1 (T2). The persistence of QoL-related side effects after 3 months from the end of the induction cycle was evaluated...
October 2018: Canadian Journal of Urology
Pierluigi Bove, Valerio Iacovelli, Maria Cristina Tirindelli, Daniele Bianchi, Gerardo Paolo Flammia, Chiara Cipriani, Angelo Salvatore Ferraro, Matteo Ferro, William Arcese, Gianluca Ingrosso, Giuseppe Vespasiani, Enrico Finazzi Agrò
Objective To evaluate the clinical value of endoscopic fibrin glue (FG) application therapy in treating hemorrhagic radiation cystitis (HRC). Patients and Methods This is a single cohort, prospective pilot study. We collected data from patients with HRC who were treated at our urology unit during the period May 2014 to December 2016. Patients with grade >=2 HRC for whom conventional therapy and trans-urethral endoscopic electrocoagulation had failed were treated with endoscopic intravesical FG. The mean follow-up was 26...
October 3, 2018: Journal of Endourology
Andreja Erman, Gregor Kapun, Sara Novak, Mojca Pavlin, Goran Dražić, Damjana Drobne, Peter Veranič
The majority of bladder cancers in humans are non-muscle-invasive cancers that recur frequently after standard treatment procedures. Mouse models are widely used to develop anti-tumor treatments. The purpose of our work was to establish an orthotopic mouse bladder tumor model and to explore early stages of implantation of cancerous MB49 cells in vivo using various labeling and microscopic techniques. To distinguish cancer cells from normal urothelial cells in mouse urinary bladders, we performed molecular characterization of MB49 cells before intravesical injection experiments...
October 3, 2018: Histochemistry and Cell Biology
John D Kelly, Wei Shen Tan, Nuria Porta, Hugh Mostafid, Robert Huddart, Andrew Protheroe, Richard Bogle, Jane Blazeby, Alison Palmer, Jo Cresswell, Mark Johnson, Richard Brough, Sanjeev Madaan, Stephen Andrews, Clare Cruickshank, Stephanie Burnett, Lauren Maynard, Emma Hall
BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment. DESIGN, SETTING, AND PARTICIPANTS: BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III, randomised controlled trial. Patients aged ≥18 yr with intermediate- or high-risk NMIBC were accrued across 51 UK centres between 1 November 2007 and 23 July 2012...
September 29, 2018: European Urology
Wei Shen Tan, Anesh Panchal, Laura Buckley, Adam J Devall, Laurence S Loubière, Ann M Pope, Mark R Feneley, Jo Cresswell, Rami Issa, Hugh Mostafid, Sanjeev Madaan, Rupesh Bhatt, John McGrath, Vijay Sangar, T R Leyshon Griffiths, Toby Page, Dominic Hodgson, Shibendra N Datta, Lucinda J Billingham, John D Kelly
BACKGROUND: There is no effective intravesical second-line therapy for non-muscle-invasive bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. OBJECTIVE: To compare disease-free survival time (DFS) between radiofrequency-induced thermo-chemotherapy effect (RITE) and institutional standard second-line therapy (control) in NMIBC patients with recurrence following induction/maintenance BCG. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, phase III randomised controlled trial accrued across 14 centres between May 2010 and July 2013 (HYMN [ClinicalTrials...
September 28, 2018: European Urology
Judith Bosschieter, Jakko A Nieuwenhuijzen, Anouk Hentschel, André N Vis, Birgit I Lissenberg-Witte, Wim den Otter, R Jeroen A van Moorselaar
PURPOSE: To compare the effect of intravesical interleukin-2 (IL-2) instillations with and without a marker lesion on time to recurrence (TTR) in non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: A prospective randomized, controlled trial was conducted. Patients with multiple non-muscle-invasive tumours were randomized for a complete or incomplete transurethral resection (TURBT), followed by 3 IL-2 instillations. The primary end point was TTR. RESULTS: These are the results of an interim analysis, which was performed due to slow accrual after which the study was closed prematurely...
September 28, 2018: Urologia Internationalis
Wojciech Krajewski, Romuald Zdrojowy, Janusz Dembowski, Sławomir Poletajew, Michał Wróbel, Mateusz Łuczak, Andrzej Tukiendorf, Anna Kolodziej
INTRODUCTION: The study aimed to analyze the influence of restaging transurethral resection of bladder tumor (reTURB) timing on outcomes in patients receiving Bacillus Calmette-Guerin (BCG) immunotherapy. MATERIAL AND METHODS: This retrospective study enrolled 491 patients with bladder cancer receiving BCG intravesical therapy between 1998 and 2016. All patients were followed up for at least 12 months and received at least 7 BCG instillations. The patients were analyzed in terms of recurrence free, progression free, and cancer specific survival (CSS)...
September 28, 2018: Urologia Internationalis
Peter Black
No abstract text is available yet for this article.
September 24, 2018: European Urology Focus
Ryosuke Murai, Yasushi Itoh, Susumu Kageyama, Misako Nakayama, Hirohito Ishigaki, Kazuo Teramoto, Mitsuhiro Narita, Tetsuya Yoshida, Keiji Tomita, Ken-Ichi Kobayashi, Akinori Wada, Masayuki Nagasawa, Shigehisa Kubota, Kazumasa Ogasawara, Akihiro Kawauchi
Patients with a history of non-muscle-invasive bladder cancer sometimes have recurrence of tumors after transurethral resection of bladder tumor treatment. To find factors related to the recurrence of non-muscle-invasive bladder cancer, we examined tissue specimens taken at transurethral resection of bladder tumor as an initial treatment. We revealed the association between prognosis of non-muscle-invasive bladder cancer and infiltration of Foxp3+ T cells that suppress anti-tumor immunity in 115 primary non-muscle-invasive bladder cancer patients retrospectively identified and followed for at least 3 months after primary transurethral resection...
2018: PloS One
Sung Han Kim, Weon Seo Park, Jae Young Joung, Kang Hyun Lee, Jinsoo Chung, Ho Kyung Seo
Idiopathic thrombocytopenia (ITP) is a bleeding disorder involving the destruction of platelets by the immune system. Systemic amyloidosis is another bleeding disorder involving amyloid deposits that create defects in coagulation and increased prothrombin and thrombin times. We report a 52-year-old man with ITP and new two-month-duration, painless gross hematuria without clot formation resulting in amyloidosis involving the ureterovesical area of the bladder. He had osteopenia, hypertension, and moderate thrombocytopenia due to ITP diagnosed 7 years previously...
2018: Case Reports in Urology
Ming-Huan Mao, Hai-Bo Huang, Xi-Ling Zhang, Kai Li, Yi-Li Liu, Ping Wang
BACKGROUND: As an inorganic compound used to treat various cancers and other diseases, arsenic trioxide (As2 O3 ) has been reported to induce cellular apoptosis in certain kinds of cancers including bladder cancer. The aim of the present study was to elucidate the crucial cooperative role of As2 O3 and intravesical bacillus Calmette-Guerin (BCG) immunotherapy and its ability to protect against bladder cancer by targeting the IER3/Nrf2 pathway. METHOD: Initially, an orthotopic bladder cancer model was established in mice by means of intravesical instillation of the human bladder cancer cell line 5637...
November 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Betsy H Salazar, Kristopher A Hoffman, Chuan Zhang, Yingchun Zhang, Yolanda Cruz, Timothy B Boone, Alvaro Munoz
OBJECTIVES: To evaluate the role that intravesical P2X2/3 purinergic receptors (P2X2/3R) play in early and advanced neurogenic lower urinary tract (LUT) dysfunction after contusion spinal cord injury (SCI) in female rats. MATERIALS AND METHODS: Female Sprague-Dawley rats received a thoracic Th8/Th9 spinal cord contusion with either force of 100 kDynes (kDy; moderate) or 150 kDynes (severe); Sham animals had no injury. Evaluations on urethane-anesthetized rats were at either two or four weeks post-SCI...
September 26, 2018: BJU International
Wei Shen Tan, John D Kelly
Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder cancer, accounts for ~75% of bladder cancer diagnoses. This disease has a 50% risk of recurrence and 20% risk of progression within 5 years, despite the use of intravesical adjuvant treatments (such as BCG or mitomycin C) that are recommended by clinical guidelines. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapeutic effect (RITE), conductive hyperthermic chemotherapy, and electromotive drug administration (EMDA), have shown promising efficacy...
September 25, 2018: Nature Reviews. Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"